However, it promotes hyperglycemia in roughly 15% of human patients (Barlow et al., 2013), presumably by promoting systemic and hepatic insulin resistance and diminishing pancreatic response to glucose (Houde et al., 2010; Lamming et al., 2012; Schindler et al., 2014; Yang et al., 2012). This evidence concerns the gene INS and Hyperglycemia.